On September 2, 2021 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reported that Raul Rodriguez, the company’s president and chief executive officer, and Dean Schorno, the company’s chief financial officer, will participate in the following virtual investor conferences in September (Press release, Rigel, SEP 2, 2021, View Source [SID1234587176]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Citi’s 16th Annual Biopharma Conference (September 8-10, 2021)

Raul Rodriguez will participate in a panel discussion entitled: "Sickle Cell, Beta-Thal, ITP & PKD – Measuring Industry Progress in Benign Hematology" on Friday, September 10th at 12:30 p.m. ET.
H.C. Wainwright 23rd Annual Global Investment Conference (September 13-15, 2021)

Dean Schorno will present a company overview, which will be available for on-demand viewing for conference attendees starting on Monday, September 13th at 7:00 a.m. ET.
Cantor Fitzgerald Global Healthcare Conference (September 27-30, 2021)

Raul Rodriguez will present a company overview on Tuesday, September 28th at 4:40 p.m. ET.
To access the live webcast of the Citi Annual Biopharma Conference panel and the Cantor Fitzgerald Global Healthcare Conference presentation, go to the Investor Relations section of the company’s website at www.rigel.com. Please connect to Rigel’s website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

On September 2, 2021 Novocure (NASDAQ: NVCR) reported that Ashley Cordova, Chief Financial Officer, and Pritesh Shah, Chief Commercial Officer, will participate in the 2021 Wells Fargo Virtual Healthcare Conference on September 10, 2021 (Press release, NovoCure, SEP 2, 2021, View Source [SID1234587195]). Ms. Cordova and Mr. Shah will take part in a fireside chat at 10:40 a.m. EDT. Ms. Cordova and Mr. Shah will also participate in one-on-one meetings with investors throughout the event.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event.

Novocure’s corporate presentation is updated periodically, and the current presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations. Novocure has used, and intends to continue to use, its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

On September 2, 2021 KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, reported that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for KAHR’s Phase 1b clinical trial of DSP107, a first-in-class CD47x41BB targeting fusion protein, in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (Press release, KAHR Medical, SEP 2, 2021, View Source [SID1234587211]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under this IND, the Company intends to initiate a Phase 1b open label, dose escalation study to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of DSP107 as monotherapy and in combination with azacytidine or with azacytidine plus venetoclax in patients with AML and MDS. The trial, expected to commence in the fourth quarter of 2021, will be conducted at The University of Texas MD Anderson Cancer Center with the previously announced investment by the Cancer Focus Fund, LP, an investment fund established in collaboration with MD Anderson to provide funding and clinical expertise to advance promising cancer therapies.

"The FDA clearance to commence our Phase 1b clinical trial for DSP107 in hematological cancers is a significant milestone for KAHR as we advance into the clinic with our second clinical study for our lead program with the backing and support of the Cancer Focus Fund," said Yaron Pereg, Ph.D., Chief Executive Officer of KAHR. "In parallel, we are making excellent progress with DSP107’s dose-escalation and expansion study as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors. We look forward to the topline results from the dose-escalation monotherapy part of the solid tumors study in addition to the initiation of the Phase 1b clinical trial in blood cancers, both expected in the fourth quarter of this year."

"KAHR’s multi-functional immuno-recruitment fusion proteins exemplify the innovative approach to cancer we seek to support," said Ross Barrett, a founder and Managing Partner of Cancer Focus Fund. "Achieving FDA clearance for the commencement of the Phase 1b clinical trial showcases KAHR’s ability to execute its regulatory strategy, and we look forward to the launch of the trial."

KAHR develops smart immune-recruitment cancer drug candidates that are designed to activate a targeted immune response by converting cancer camouflage into beacons for the immune system to attack. The Company’s lead product candidate, DSP107, is a first-in-class CD47x41BB targeting compound that simultaneously binds cancer cells and immune cells, linking them together for maximal activation of the immune system against the tumor. DSP107 is designed to weaken the tumor’s defenses on one hand, and activate an effective, local response of both innate and adaptive immunity on the other hand. Specifically, DSP107 binds to and inhibits CD47, an immune checkpoint protein overexpressed in many cancer types that enables the tumor to evade immune recognition and attack. Simultaneously, DSP107 binds 41BB on T-cells, stimulating their activation. These activities lead to targeted immune activation through both macrophage and T-cell mediated tumor destruction.

On September 2, 2021 Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, reported that the Company will present at the following upcoming investor conferences (Press release, Fate Therapeutics, SEP 2, 2021, View Source [SID1234587230]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2021 Virtual Wells Fargo Healthcare Conference on Thursday, September 9, 2021, at 10:40 am ET
Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 11:00 am ET
H.C. Wainwright 23rd Annual Global Investment Conference available on demand on Monday, September 13 at 7:00 am ET
Baird’s 2021 Global Healthcare Conference on Wednesday, September 15 at 12:15 pm ET
Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22 at 4:35 pm ET
2021 Cantor Virtual Global Healthcare Conference on Wednesday, September 29 at 10:40 am ET
A live webcast, if recorded, of each presentation can be accessed under "Events & Presentations" in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.

On September 2, 2021 Evotec partner Kazia Therapeutics Limited ("Kazia", ASX: KZA; NASDAQ: KZIA) reported that the planned phase I study for EVT801 has received full approval from L’Agence Nationale de Sécurité du Médicament et des Produits de Santé ("ANSM"), the French regulatory agency (Press release, Evotec, SEP 2, 2021, View Source;announcements/press-releases/p/evotec-partner-kazia-therapeutics-announces-full-regulatory-approval-for-phase-i-study-of-evt801-6092 [SID1234587161]). The study is expected to open to recruitment by the end of CY2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evotec and Kazia entered into both a licensing and master service agreement in April 2021. Under the contract, Evotec grants Kazia an exclusive worldwide license for research, development and commercialisation of Evotec’s oncology project EVT801, a small molecule inhibitor of the lymphatic growth factor receptor VEGFR3, originally developed within Evotec’s partnership with Sanofi.

Kazia CEO, Dr James Garner, commented: "since concluding our license agreement with Evotec in April, we have made exceptionally swift progress in bringing EVT801 to the clinic. We have been grateful for the exceptional efforts of the Evotec team, working closely with Kazia colleagues to drive the project forward. The study that we have designed is highly innovative, which befits the rich potential of EVT801, and we look forward to commencing recruitment in the near future."